Objective: The nuclear receptor PPARg is the master regulator of adipocyte differentiation, distribution, and function. In addition, PPARg induces terminal differentiation of several epithelial cell lineages, including colon epithelia. Loss-of-function mutations in PPARG result in familial partial lipodystrophy subtype 3 (FPDL3), a rare condition characterized by aberrant adipose tissue distribution and severe metabolic complications, including diabetes. Mutations in PPARG have also been reported in sporadic colorectal cancers, but the significance of these mutations is unclear. Studying these natural PPARG mutations provides valuable insights into structure-function relationships in the PPARg protein. We functionally characterized a novel FPLD3-associated PPARg L451P mutation in helix 9 of the ligand binding domain (LBD). Interestingly, substitution of the adjacent amino acid K450 was previously reported in a human colon carcinoma cell line. Methods: We performed a detailed side-by-side functional comparison of these two PPARg mutants. Results: PPARg L451P shows multiple intermolecular defects, including impaired cofactor binding and reduced RXRa heterodimerisation and subsequent DNA binding, but not in DBD-LBD interdomain communication. The K450Q mutant displays none of these functional defects. Other colon cancer-associated PPARg mutants displayed diverse phenotypes, ranging from complete loss of activity to wildtype activity. Conclusions: Amino acid changes in helix 9 can differently affect LBD integrity and function. In addition, FPLD3-associated PPARg mutations consistently cause intra-and/or intermolecular defects; colon cancer-associated PPARg mutations on the other hand may play a role in colon cancer onset and progression, but this is not due to their effects on the most well-studied functional characteristics of PPARg.
INTRODUCTION
Unraveling the complex genetics and molecular and cellular mechanisms in adipose tissue physiology improves the understanding of adipose tissue dysfunction and its related metabolic complications. Adipose tissue dysfunction is a hallmark of pathologic conditions including obesity, type 2 diabetes mellitus (T2DM), and lipodystrophies. The nuclear receptor peroxisome proliferator-activated receptor g (PPARg), encoded by the PPARG gene, is the master regulator of adipocyte differentiation, maintenance, and function [1] . Differential promoter usage and alternative splicing generates two major protein isoforms, PPARg1 and PPARg2 [2] . PPARg1 is highly expressed in colon epithelial cells, adipocytes, and monocytes/ macrophages. PPARg2 contains an additional 28 amino acids at the Nterminus and is predominantly expressed in adipose tissue [1] . Both PPARg isoforms are essential in adipogenesis [3] . PPARg forms an obligatory heterodimer with RXRa [4] . The PPARg/ RXRa heterodimer regulates the transcription of PPARg responsive genes by binding to PPAR-response elements (PPRE) in the promoter and/or enhancer regions. The PPARg cistrome is gene-and cell typespecific [5] . In the absence of a ligand, PPARg/RXRa heterodimers are able to bind to PPREs. Transcription is actively repressed via interactions with corepressors like NCoR and SMRT, which recruit histone deacetylases. Upon ligand binding, the PPARg ligand binding domain (LBD) undergoes a conformational change that causes the release of the corepressors and binding of coactivators like SRC-1 and CBP, initiating transcription of PPARg target genes. PPARg can be activated by various endogenous ligands including polyunsaturated fatty acids and eicosanoids [6, 7] . PPARg is the cognate receptor for thiazolidinediones, a class of anti-hyperglycemic agents, including rosiglitazone and pioglitazone [8] . Despite their beneficial effects in glycemic control, the clinical use of thiazolidinediones is restricted due to their side effects [9] . Loss-of-function mutations in the PPARG gene cause familial partial lipodystrophy subtype 3 (FPLD3), a rare clinical condition characterized by progressive and gradual change of subcutaneous adipose tissue distribution during peripubertal phase [10e15] . FPLD3 patients have a marked muscular appearance due to a paucity of subcutaneous adipose tissue in the extremities and gluteal region with co-existent lipohypertrophy in face, neck, and trunk. Patients manifest with T2DM, hepatic steatosis, recurrent episodes of pancreatitis, eruptive xanthomata, and pronounced acanthosis nigricans. The co-segregation of lipodystrophy with mutations in PPARG underscores the importance of PPARg for adipocyte biology. In addition, PPARg also induces the terminal differentiation in several other cell lineages, including colon, breast, prostate, and lung epithelial cells [1] . Somatic PPARG mutations have been reported in sporadic colorectal carcinomas, but functional characterization is limited and complete sideby-side comparison of their activity in a given experimental setting is currently lacking [16, 17] . In addition, high expression levels of PPARG, but no PPARG mutations, have been reported in certain cancer cell lines, including breast cancer [18] and prostate cancer [19] . Hemizygous deletions of PPARG have also been described in prostate cancers [19] . Therefore, the importance of PPARg in tumor initiation and progression is not exactly known. However, PPARg ligands can inhibit tumor growth [17e19], and TZDs synergistically enhance carboplantin-mediated tumor growth inhibition in a PPARg-dependent fashion in various types of cancer [20, 21] . This synergistic effect is partly explained by a PPARgmediated downregulation of methallothioneins [20] or increased DNA damage and subsequent p53-mediated apoptosis [22] . Here we report the identification and functional characterization of a novel natural PPARg L451P mutant in a family affected by FPLD3. Interestingly, substitution of the adjacent amino acid K450 was previously described in a human colon carcinoma cell line refractory to PPARg-ligand induced growth inhibition [17] . Here we show that, in contrast to the tumor-associated K450Q mutant, the FPLD3-associated L451P mutant significantly impairs the transcriptional activity of PPARg due to a range of molecular defects. Our findings support the view that FPLD3-associated mutations consistently cause intra-and/or intermolecular defects, while the effect of colon cancer-associated PPARg mutations varies considerably, suggesting subtler or contextdependent effects.
MATERIALS AND METHODS

Case presentation
Written informed consent for study participation and publication was obtained from the patient. The index patient was referred because of a suspicion of lipodystrophy (Figure 1AeF , detailed patient description is available in the Supplemental Data). We subjected the index patient to whole exome sequencing to identify the gene responsible for the lipodystrophic phenotype. Considering the family medical history, we performed a pedigree analysis. The patient's mother was originally diagnosed with T2DM, hypertension, and hypertriglyceridemia. Furthermore, she was suffering from ischemic heart disease. The patient's sister and aunt were both initially diagnosed with T2DM and hypertriglyceridemia. The index patient's brother, who was seemingly unaffected albeit slightly overweight, appeared to have a mild T2DM and clear hypertriglyceridemia (Supplemental Data). We sequenced the candidate variant in several family members.
Materials
Rosiglitazone maleate was from Alexis. WY14643 was from Enzo Life Sciences. 15-deoxy-D12,14-prostaglandin J2 (abbreviated as 15d-PGJ2), was from Cayman Chemicals. Synthetic RXRa agonist 6-[1- (3,5,5,8,8-pentamethyl-5,6 ,7,8-tetrahydronaphthalen-2-yl)cyclopropyl]nicotinic acid (abbreviated as LG100268) was purchased from SigmaeAldrich. Anti-PPARg (sc-7196; RRID: AB_654710), antiPPARa (sc-9000; RRID: AB_2165737), anti-PPARa (sc-1985; RRID: AB_2165740), anti-Gal4 DBD (sc-510; RRID: AB_627655), anti-RXRa (sc-553: RRID: AB_2184874), and anti-tubulin (Sigma Aldrich T9026: RRID: AB_477593) used for western blotting, were from Santa Cruz Biotechnology, Inc. Protein A Sepharose 4B Fast Flow beads were from SigmaeAldrich.
2.3. DNA sequence analysis Genomic DNA was extracted from peripheral-blood leukocytes in venous blood samples using QIAamp DNA Blood Mini Kit (Qiagen Hilden, Germany). Whole exome sequencing, mapping, and data analysis were performed as described previously [23] . The mutation identified in the index patient, corresponds to c.1352T > C and p.L451P in reference sequences NM_015869 and NP_056953.2, respectively. The identified genetic variant was validated by Sanger sequencing. The variant p.L451P was absent in the variation databases NHLBI GO Exome Sequencing Project (ESP) [24] , 1000 Genomes [25] , and Single Nucleotide Polymorphism Database (dbSNP) [26] , and The Genome Aggregation Database (gnomAD) [27] . Amplification and Sanger sequencing of exon 6 and flanking regions were performed to genotype family members. Primers are available upon request.
Plasmids
The luciferase reporter 3xPPRE-tk-Luc was kindly provided by Dr. R.M. Evans. pGL3-mFabp4-Tk-Luc (fatty acid binding protein 4; Fabp4) was a kind gift from Dr. S. Mandrup. pGL3-mCidec-Luc (cell-deathinducing DFFA-like effector c; Cidec) was a kind gift from Dr. P.F. Marrero Gonzales. The reporter construct 5xGal4-E1BTATA-pGL3 has been described previously [28] . pCDNA3.1 vectors containing the complete coding region of hPPARg2 wildtype (WT), a kind gift from Dr. V.K.K. Chatterjee [29] , and Gal4DBD-hPPARg-AF2 WT (amino acids 204-507) [12] were used to generate R181D/R183D, K450Q, K450P, L451G, L451P, and E455K mutants using QuikChange mutagenesis kit (Stratagene). pCDNA3.1-hPPARg1 was used for generating Q268P, R288H, S289C, V290M, K319X, K422Q, and L423P. S414P was generated in the pCDNA3.1 vector containing PPARa. pGEX-PPARg LBD WT was used to generate the K450Q and L451P mutants. Successful mutagenesis was verified by Sanger sequence analysis. pCDNA3.1 vectors containing RXRa, PPARg L464R, and PPARg L496A/E499A have been described previously [12, 29] . pGEX constructs containing RXRa, SRC1 (AA 570-780), SMRT (AA 2302-2352), and PGC1a (AA 1-338) have been described previously [12,30e32] 2.5. Cell culture and reporter assays For luciferase-based reporter assays the human osteosarcoma cell line U2OS and the human embryonic kidney cell line HEK293T were maintained in DMEM 4.5 g/L D-glucose supplemented with 10% fetal calf serum (Invitrogen), and 100 mg penicillin/ml and 100 mg streptomycin/ml (Invitrogen). Cells were transfected using the calcium phosphate precipitation method as described previously [12] . The results are averages of at least three independent experiments assayed in duplicate AE SEM. Student's t-tests were used. A statistically significant difference was defined as a p value of p < 0.05.
Western blot analysis
The protein expression of the transfected U2OS and HEK293T cells was determined by western blot analysis as described [12] . AntiPPARg, anti-PPARa, anti-Gal4 DBD, anti-RXRa, and anti-Tubulin were used for detection of the proteins. Enhanced chemiluminescence (Amersham Biosciences) was used for visualization.
NR-coregulator interaction analyses
The NR-Coregulator interaction profiling was performed as described previously [31, 33] . GST-pull down assays were performed as described previously [12] .
2.8. EMSA EMSAs were performed as described [12] . Double-stranded DNA oligomers containing a consensus PPRE and natural PPREs derived from Fabp4 (ARE6) and Cidec promoters were labeled with [g-32P] deoxy-ATP using T4 polynucleotide kinase (Biolabs). For binding and competition analysis the following DNA oligomers were used: consensus PPRE sense probe 5 0 CCGGGGACCAGGACAAAGG-TCACGAAGCT 3 0 (underlined characters indicate the DR1 element), mutant consensus PPRE sense probe 5 0 CCGGGGACCAGCACAAA-GCACACCGAAGCT 3 0 ; mouse Fabp4 sense probe 5 0 CTCTCTGG-GTGAAATGTGCATTTCT 3 0 , and mouse Cidec sense probe 5 0 CTGTGCCCTCTTGCCTAGTGC 3 0 .
2.9. Association of genetic variants with FPLD3 phenotype in index patient PCR was performed in the index patient to genotype the lead SNPs in 53 genomic regions that were previously identified to impair peripheral adipose tissue storage [34] . Primer sequences are available upon request. Upon download of the full dataset SNPs were extracted based on rsID from the imputed dataset (EGAS00001001232_UKHLS.UK10Kþ1 KGimputed.phwe_1e-4.info_0.4.filtered). These SNPs were further processed using plink (v. 1.9b3) to extract compound genotypes and dosage. A custom R script (code and data attached in supplement) was used to further process these data and calculate the number of risk alleles in the population and calculate a Z-score.
2.10. Molecular modeling PPARg-RXRa nuclear receptor complex Molecular Modeling of loop 9/10 of PPARg with and without the L451P mutation was performed using Rosetta 3.8 [35] . Briefly, modeling was based on the structure of the PPARgeRXRa Nuclear Receptor Complex (PDB ID 3DZY) [36] . A set of 3000 models was built for the WT and L451P variant respectively, using the kinematic loop modeling protocol [37] followed by a relaxation of the structures. The structures were clustered using Calibur [38] . All models were evaluated based on energy and cluster size. Visualization and image generation was done using the PyMOL Molecular Graphics System Version 1.8 (2015) provided by SBGrid [39] .
RESULTS
Identification of the novel PPARg L451P mutant in a family affected by FPLD3
Whole exome sequencing (WES) of the index patient revealed a heterozygous missense mutation in exon 6 (genomic position: chromosome 3:12475478, corresponding to c.1352T > C in reference sequences NM_015869 and NP_056953.2, respectively) in the gene PPARG, which causes the substitution of a leucine residue located at position 451 into a proline (p.L451P). This genetic variant was absent in the variation databases; the Genome Aggregation Database [27] contains the rare variant p.L451V, but whether this variant has any clinical implications, is unknown as information regarding phenotype are not available.
The clinical characteristics of the index patient closely resemble previously described cases of FPLD3, including lipodystrophy in the upper-and lower extremities with preserved truncal adipose tissue ( Figure 1A , DeF), and acanthosis nigricans ( Figure 1B ,C). Paternal and maternal family history showed T2DM and hypertriglyceridemia ( Figure 1G) . This prompted us to analyze the pedigree of the index patient (III-2). The mutation was identified in her mother (II-4), sister (III-4), and an aunt (II-2). All had a clear lipodystrophic phenotype and a medical history comprising T2DM, hypertriglyceridemia, and/or cardiovascular disease. The PPARG mutation was also identified in the index patient's brother (III-1). The redistribution of adipose tissue was less obvious in the brother, he was diagnosed with T2DM during the study.
A recent population-level genetic study identified 53 genomic regions in which single nucleotide polymorphisms (SNPs) are associated with insulin resistance [34] . An increased number of these risk alleles is associated with an impaired ability to store adipose tissue in peripheral compartments [34] . While rare variants in PPARG certainly contribute to lipodystrophy, this study suggests that SNPs in regulatory regions may contribute too. Our index patient harbors 53 risk alleles ( Figure 1I ; Supplemental Table 1 ). To determine whether our patient is at an increased risk for a lipodystrophic phenotype based on her genetic background, we constructed a genetic background distribution in a healthy female population (UKHLS GWAS dataset (EGA accession EGAD00010000890); n ¼ 5,296 female). Compared to this population distribution the index patient is not at increased risk (zscore ¼ À1.28). Taken together, the lipodystrophic phenotype in our index patient is most likely due to the novel PPARG L451P mutation.
3.2. The FPLD-associated mutant L451P, but not the colon cancerassociated mutant K450Q, displays impaired transcriptional activity The mutation identified by WES alters a leucine residue located at position 451 at the C-terminus of helix 9 into a proline ( Figure 1J ). While L451P is the first FPLD3-associated PPARg2 mutant in helix 9 of the LBD, a previous study in human colon cancer cells lines reported a K422Q mutant in PPARg1, which corresponds to K450Q in the PPARg2 protein ( Figure 1J ) [17] . As the amino acid sequence of PPARg2 helix 9, including K450 and L451, is highly conserved among species (Supplemental Figure 1) , we compared the ability of the natural L451P and K450Q mutants and some artificial mutants to activate PPARg-mediated transcription in reporter assays. These experiments were conducted in the human osteosarcoma cell line U2OS, which express negligible levels of endogenous PPARg but display robust activation upon PPARg overexpression and induction [26, 40] . The transcriptional activity of the L451P mutant on a reporter construct containing three copies of a consensus PPRE (3xPPRE) was significantly impaired under both basal and induced conditions compared to the WT protein in U2OS cells ( Figure 2A ) and in HEK293T cells (data not shown). Increasing L451P protein concentrations led to a proportional increase in transcriptional activity, but the mutant never reached WT levels (Supplemental Figure 2) . Additional mutants were analyzed to characterize the functional defect better. Mutation of L451 into a glycine residue (L451G), which may also potentially disrupt helix 9, showed no clear effect (Figure 2A ). The K450Q mutant activated The activation of 3Â peroxisome proliferator response element (PPRE)-Tk-Luc reporter (A and C), Cidec-(B), or Fabp4-Luc reporter (B), in the absence or presence of 1 mM rosiglitazone (PPARg) or 100 mM Wy14643, is expressed as fold induction over that with empty vector (EV). D. U2OS cells were transfected with equal amounts of plasmids harboring PPARg2 WT, L451P, and L496A/E499A in absence and presence of 1 mM rosiglitazone. Results are averages of at least three independent experiments assayed in duplicate AE SEM. *P < 0.05; **P < 0.01 cells transfected with mutant vs. WT. Expression levels of the different proteins were confirmed by western blot analysis using a PPARg or PPARa specific antibody. The arrow indicates PPARg and the asterisk indicates an unknown non-specific band. WT, wildtype. transcription similar to the PPARg2 WT protein (Figure 2A and data not shown). Substitution of lysine 450 into a proline (K450P) however impaired transcriptional activity similar to the L451P mutation ( Figure 2A, left panel) . Similar results were obtained with 15d-PGJ2, a potential natural PPARg ligand (Supplemental Figure 3) . Increasing ligand concentrations did not compensate for the transcriptional defect observed (data not shown). The analogous mutation in the PPARg1 isoform (L423P) displayed a similar defect (Figure 2A, right panel) . In agreement with our findings for PPARg2, the K-to-Q mutation (K422Q, corresponding to K450Q in PPARg2) did not impair transcriptional activity. Next, the PPARg L451P mutant was tested on reporter constructs that harbor the promoter regions of the well-characterized PPARg target genes Cidec and Fabp4. The PPARg2 L451P mutant also shows impaired transcriptional activity on these natural PPREcontaining promoters ( Figure 2B ). The amino acid sequence and structure of PPARg2 helix 9 is highly conserved among species (Supplemental Figure 1) . The human PPARg, PPARa, and PPARd proteins share a high degree of homology in the sequence and structure of their LBDs, but K450 and L451 positions in PPARg are not conserved between the 3 PPAR isotypes (Supplemental Figure 1) . Substitution of serine 414 into a proline in PPARa, which corresponds to L451P in PPARg, however, clearly inhibited the transcriptional activity of this protein ( Figure 2C ). The amino acid corresponding to K450 in PPARg2 is a glutamine residue in both PPARa and PPARd, suggesting that either a lysine or a glutamine residue is structurally tolerated at this position. This view is supported by the lack of phenotype observed with the PPARg2 K450Q mutant (Figure 2A ). Previous studies show that FPLD3-associated PPARg2 mutants exert their pathogenic effects by either haploinsufficiency or dominant negative activity towards the PPARg2 wildtype protein on the level of DNA binding or cofactor binding [10] . Reporter assays using cells transfected with both PPARg wildtype and L451P showed no decrease in transcriptional activity when compared with cells transfected with PPARg wildtype alone, indicating that the L451P mutant exhibits no dominant-negative activity in this assay ( Figure 2D ). In contrast, the artificial L496A/E499A mutant displayed a strong dominant negative activity, as shown earlier [12, 29] . Taken together, these finding show that disruption of helix 9 by proline residues (PPARg2: L451P, K450P; PPARg1: L432P; PPARa: S414P) negatively affects PPAR function, while the natural K450Q mutation in helix 9 has no clear effect.
3.3. The L451P substitution shows that PPARg activity does not crucially depend on PPARg DBD-LBD interdomain communication Next, we wished to identify the molecular defects of the L451P mutant (Figure 2) . A recent structural and functional study on the multi-domain RARb-RXRa heterodimer revealed that physical interactions between the RARb DBD and LBD are implicated in allosteric signal transmission between the domains [41] . Apart from important differences in quaternary structure between the RARb-RXRa and PPARgeRXRa heterodimers [41] , an intramolecular interaction interface -though smaller than in RARb -is also present between the PPARg LBD, involving the loop between helix 9 and 10, and PPARg DBD [36, 41] (Figure 3AeC ). We investigated whether the L451P substitution would interfere with the DBD-LBD interface by functionally assessing the importance of this interface for the transcriptional activity of PPARg. Remodeling experiments on the quaternary PPARgeRXRa heterodimer structure revealed physical interactions between a glutamic acid residue at position 455 in the loop connecting helix 9 and 10 with arginine and histidine residues at position 181 and 183 of the PPARg DBD, Original Article respectively (Figure 3AeC ). Introducing mutations at the PPARg2 LBD-DBD interface did not compromise the transcriptional activity of PPARg2 ( Figure 3D ). Our data suggest that in contrast to the larger and well-formed RARb LBD-DBD interface [41] , transcriptional activity of PPARg does not crucially depend on the transmission of allosteric signals between the DBD-LBD intramolecular interface. Therefore, the impact of L451P on this intramolecular interdomain communication is probably limited.
L451P causes a general ligand-mediated cofactor binding defect
The position of L451P in the LBD suggests that it can potentially disrupt intermolecular interactions, such as ligand-mediated cofactor interactions and/or RXRa heterodimerisation. To address these options, we first performed reporter assays in which PPARg driven transcription relies on ligand-mediated cofactor recruitment, but is independent of heterodimerisation with RXRa [12] . For this, the mutations described above were introduced into a chimeric Gal4DBD-PPARg LBD receptor and expressed together with a Gal4 reporter gene in U2OS cells. Both the wild type Gal4-PPARg LBD receptor and the dimerization defective L464R mutant [12] clearly activated transcription, but the L451P mutant displayed reduced activity ( Figure 4A ). The activity of the K450Q protein was comparable to the WT version, similar to our findings with the full-length protein ( Figure 2 ). Even high concentrations of thiazolidinediones, including rosiglitazone and pioglitazone, or the tyrosine-based agonist GW1929 were unable to restore the transcriptional activity to WT levels (data not shown).
To further analyze the interaction of the L451P mutant with transcriptional cofactors, we performed MARCoNI assays, a peptide-based microarray containing 154 NR binding motifs present in different coactivators and corepressors [31, 33] . The NR-coregulator interaction profiles showed an overall impairment of binding, both in the absence and in the presence of rosiglitazone ( Figure 4B and Supplementary  Figure 3) . In contrast, the K450Q mutant protein displayed binding profiles similar to the WT protein (data not shown). Independent GST pulldown experiments confirmed that PPARg L451P, but not K450Q, interacts less efficiently in absence and presence of ligand with coactivators PGC1a and SRC1 and corepressor SMRT ( Figure 4C ). Together, these results indicate that mutation of L451 into proline, but not K450 into glutamine, causes a general ligand-mediated cofactor binding defect.
3.5. The L451P substitution disrupts PPARg/RXRa heterodimerization and DNA binding As leucine 451 is located relatively close to the RXRa binding interface in the LBD [36, 42] (Figure 1J ), and RXRa heterodimerization is essential for subsequent DNA binding [4] , we also examined the effect of the L451P substitution on these PPARg functions. First, we performed in vitro binding assays using GST-RXRa and [
35 S]-methionine labeled PPARg (wildtype and mutants). A clear reduction in RXRa heterodimerization was observed when comparing the L451P mutant protein to the WT version ( Figure 5A ). The K450Q mutation did not affect RXRa heterodimerization ( Figure 5A ), in agreement with previous data [17] . Similar findings were made when using GST-PPARg-LBD and [ 35 S]-methionine labeled RXRa (data not shown). To confirm and extend these findings in a cellular setting, we performed mammalian two-hybrid reporter assays in which we tethered PPARg LBD WT and mutant versions to the DNA and coexpressed RXRa, either in the absence or presence of a synthetic RXRa ligand (LG 100268). In this setting, reporter activity depends on the interaction between the transcriptionally silent Gal4-DBDehPPARg-LBD protein and its ligandactivated RXRa binding partner ( Figure 5B ). While the activity of Gal4-DBDehPPARg-LBD WT and K450Q could be stimulated by RXRa and further enhanced by LG100268, the L451P protein showed only weak activity under these conditions. As a control, we used the dimerizationdefective L464R mutant [12] , which indeed failed to respond to the addition of RXRa protein ( Figure 5B) . Therefore, we conclude that substitution of L451 into proline impairs heterodimerization with RXRa; the K450Q mutant displayed no obvious dimerization defect. To investigate the consequences of impaired RXRa interaction on binding of the PPARg/RXRa heterodimer to DNA, we performed electrophoretic mobility shift assays (EMSA) using a consensus PPRE and PPREs derived from the Fabp4 and Cidec genes. Binding of the L451P mutant protein was impaired on all 3 DNA elements, which was most pronounced when lower amounts of protein were tested ( Figure 5C ). As a control, we again used the dimerization-defective L464R mutant [12] , which indeed failed to bind DNA ( Figure 5C ). Taken together, these data indicate that the FPLD-associated L451P mutation results in impaired transcriptional activity due to impaired cofactor binding and reduced DNA binding, while the adjacent K450Q mutant, which was found in a human colon cancer cell line [17] , displays no clear functional defects.
Colon cancer-associated PPARg mutants display variable phenotypes
The FPLD3-associated PPARg mutants reported so far, including the currently characterized PPARg2 L451P, all show a consistent and profound impairment in PPARg transcriptional activity due to different repertoires of inter-and intramolecular defects [10e15]. Our functional characterization of the colon cancer-associated PPARg2 K450Q (corresponding to PPARg1 K422Q) suggests that K450Q does not display major functional defects, at least under our experimental settings. To determine whether this is a general feature of colon carcinoma-associated PPARg1 mutants, we performed a side-by-side analysis of other previously reported colon cancer-associated PPARg1 mutants Q286P, R288H, and K319X [16, 17] . Two additional mutants were included, S289C [43] and V290M [10] . PPARg1 S289C is the first PPARG germline mutation that is associated with dyslipidemia and colonic polyp formation with progression to full-blown adenocarcinoma, without features of FPLD3 [43] . PPARg1 V290M is one of the first identified FPLD3-associated mutants [10] . Whereas the activity of PPARg1 mutants Q286P and K319X is negligible in presence of rosiglitazone and 15d-PGJ2, the transcriptional activity of PPARg1 R288H, alike K422Q, is clearly not impaired when induced with rosiglitazone ( Figure 6B ). In line with a previous study [16] , impaired transcriptional activity was observed when PPARg1 R288H was treated 15d-PGJ2, a potential natural PPARg ligand. Although PPARg1 mutants S289C and V290M were both still able to initiate transcription, their activity was impaired ( Figure 6B ), in agreement with previous reports [10, 43, 44] . Interestingly, the transcriptional activity of PPARg1 S289C reached wildtype levels upon induction with 15d-PGJ2. Collectively, these results indicate that the colon carcinoma-associated PPARg mutants have diverse effects on transcriptional activity and suggest that colon carcinoma-associated PPARG mutations, in contrast to FPLD3-associated PPARG mutations, do not always lead to robust molecular defects. Accordingly, if the PPARG mutations are related to colon cancer onset and progression, this is not due to their effects on the most well-studied functional characteristics of PPARg. 
DISCUSSION
Here we show that the novel heterozygous PPARg L451P mutation likely provides the molecular basis for the lipodystrophic phenotype in the index patient and her family. Although this is the first FPLD3-associated PPARG mutation located in helix 9, the adjacent lysine amino acid was found to be mutated (K450Q) in colorectal cancer cell lines [17] . The L451P mutant displays reduced transcriptional activity due to multiple molecular defects, including 1) general defects in ligand-mediated cofactor interactions and 2) impaired DNA binding due to reduced RXRa heterodimerization. In contrast, the K450Q mutant behaved like the wild type protein under all our experimental settings, suggesting that only dramatic amino acid changes in helix 9 will result in impaired PPARg function. Noteworthy, our side-by-side analysis of the FPLD3-associated PPARg L451P and V318M with the previously reported colon cancer-associated PPARg mutants Q286P [17] , R288H [17] , S289C [43] , K319X [17] , and K422Q [16] , shows that the colon cancer-associated PPARg mutants do not always cause profound intra-and/or intermolecular defects. Interestingly, while no clear molecular defects with the K450Q mutant in PPARg2 (present study) or the analogous K422Q mutant in PPARg1 [17] could be identified, the PPARg1 K422Q mutant failed to induce growth inhibition in vitro and in vivo and to induce intestinal epithelial cell differentiation when compared to the wild type protein [17] . In addition, PPARg1 mutant S289C seems to be at the nexus of colon tumorigenesis and metabolic diseases as only the mutation carriers displayed derangements in lipid profiles without clinical features of T2DM and FPLD3 and only the mutation carriers developed dysplastic colonic polyps during the fourth-fifth decade of life, which in one patient progressed to colon cancer [43] . Together, these findings suggest that combined PPARg transcriptome, cistrome, and interactome analyses within a specific cellular context may be required to identify specific phenotypic defects. Although members of the nuclear receptor superfamily share a common structural architecture between their LBDs, the leucine residue at position 451 in PPARg is not conserved (Supplemental Figure 1) . As shown here, mutation of the corresponding position in PPARa reduced transcriptional activity (S414P; Figure 2A ), while artificial mutants at this position in the vitamin D receptor (VDR; VDR C369G [45] ) and thyroid hormone receptor b (THRb; THRb Y409K and neighboring residues Y406K, and R410A [46] ) also show impaired LBD functions, including dimerization defects and impaired ligand-and cofactor binding. Together these findings support the view that L451 helps to maintain the integrity of helix 9, and that this helix is important for other nuclear receptors to function properly too. To the best of our knowledge, no naturally occurring mutations corresponding to the L451 position in PPARg have been reported in other nuclear receptors so far. In light of studying genetic PPARG variants and their effect on function, the recently developed classifier Missense InTerpretation by Experimental Response (MITER, available at http://miter.broadinstitute.org) is of particular interest [15] . MITER was generated by evaluating the effects all 9,595 possible single amino acid substitutions in PPARg on CD36 expression using the human monocytic cell line THP- The co-segregation of FPLD3 with the mutant receptor PPARg L451P that displays reduced transcriptional activity due to multiple molecular defects, strongly indicates that this variant is causal for the condition. However, the molecular defects of the L451P mutant are subtler than previously reported FPLD3-associated PPARg mutants, indicating that the index patient and affected family members may harbor additional co-segregating genetic variants that contribute to the lipodystrophic phenotype. Indeed, recent studies have shown that FPLD syndromes have a polygenic component. The importance of SNPs in regulatory regions in lipodystrophy has recently been depicted in a large population-level genetic study [34] . Patients with FPLD1, a subtype of FPLD with hitherto unknown genetic cause, are enriched for 53 common variants associated with limited peripheral adipose tissue storage capacity [34] . These observations not only suggest a polygenetic cause of FPLD1 [34] , but also imply that genetic background affecting adipose tissue expandability can contribute to the penetrance of other types of lipodystrophy. The risk score analysis (z-score ¼ À1.28) of the 53 loci in the index patient indicated that the index patient is not fully predisposed to a lipodystrophic phenotype based on her genetic background at these 53 SNPs. However, our catalog of genetic modifiers for FPLD is far from complete. Whereas the previously identified 53 genomic loci have been identified in subjects who are predominantly from European Caucasian origin, it remains to be defined to what extent the identified risk alleles can be applied to subjects of other genetic ancestries. The index patient in the current study is from Turkish descent and we cannot exclude that other genetic factors modify the FPLD3 phenotype. Furthermore, recent work suggests that other non-coding SNPs can modulate human metabolic disease risk by altering PPARg binding [47] . Information from across the genome and from detailed mechanistic studies such as ours will continue to improve risk classification.
In conclusion, extensive characterization of the PPARg L451P mutant identified here in a family affected by FPLD3 at the clinical, cellular, molecular, and genetic level revealed valuable understanding of PPARg structure and function. We show that the newly identified FPLD3-associated L451P mutant significantly impairs the transcriptional activity of PPARg due to a range of molecular defects that disrupt intermolecular interactions, while leaving the intramolecular LBD-DBD interactions largely intact. In contrast, the colon cancer-associated PPARg K450Q mutation does not robustly affect PPARg function, indicating that amino acid changes at the C-terminus of helix 9 can have differential effects on LBD integrity. Previous analyses of natural PPARg mutants together with the data presented here support the view that FPLD3-associated mutations consistently cause intra-and/or intermolecular defects, while the effect of colon cancer-associated PPARg mutations varies considerably, suggesting subtler or contextdependent effects.
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